Abstract：
BACKGROUND: Chronic hepatitis B (HB) remains a significant global health concern, despite the widespread availability of the HB vaccine. While the standard vaccine demonstrates an impressive serological response rate exceeding 90%, a subset of individuals exhibit suboptimal immunity. This study aims to elucidate the efficacy of the AS04C-adjuvanted HB vaccine in addressing non-responsiveness.
METHODS: Conducted at the Preventive Medicine Service of the University Albacete Hospital in Spain from 2017 to 2021, this single-center observational study enrolled 195 patients. Among them, 126 (65%) were classified as non-responders following one or two complete standard vaccination courses.
RESULTS: After the administration of a complete four-dose regimen of the AS04C-adjuvanted vaccine, 73.81% of non-responder patients exhibited antibody titers indicative of robust immunity (anti-HBs >10).
CONCLUSIONS: These findings underscore the pivotal role of the AS04C-adjuvanted HB vaccine in addressing non-responsiveness, emphasizing its potential as a crucial tool in augmenting immunization strategies for various populations. This includes non-responders to standard vaccination, individuals with chronic kidney disease, those requiring seroprotection due to factors like immunosuppression or occupational hazards, as well as patients for whom conventional revaccination strategies have proven futile. Additional research is needed to expand on the promising results obtained through our protocol.
METHODS: Conducted at the Preventive Medicine Service of the University Albacete Hospital in Spain from 2017 to 2021, this single-center observational study enrolled 195 patients. Among them, 126 (65%) were classified as non-responders following one or two complete standard vaccination courses.
RESULTS: After the administration of a complete four-dose regimen of the AS04C-adjuvanted vaccine, 73.81% of non-responder patients exhibited antibody titers indicative of robust immunity (anti-HBs >10).
CONCLUSIONS: These findings underscore the pivotal role of the AS04C-adjuvanted HB vaccine in addressing non-responsiveness, emphasizing its potential as a crucial tool in augmenting immunization strategies for various populations. This includes non-responders to standard vaccination, individuals with chronic kidney disease, those requiring seroprotection due to factors like immunosuppression or occupational hazards, as well as patients for whom conventional revaccination strategies have proven futile. Additional research is needed to expand on the promising results obtained through our protocol.
摘要：
背景：慢性乙型肝炎（HB）仍然是一个重要的全球健康问题，尽管广泛使用HB疫苗。虽然标准疫苗表现出超过90％的令人印象深刻的血清学应答率，一个子集的个体表现出次优的免疫力。这项研究旨在阐明AS04C佐剂化的HB疫苗在解决非反应性方面的功效。
方法：2017年至2021年在西班牙阿尔巴塞特大学医院预防医学服务处进行，这项单中心观察性研究招募了195名患者。其中,在一个或两个完整的标准疫苗接种过程后，126（65％）被归类为无反应者。
结果：在使用完整的四剂量方案的AS04C佐剂疫苗后，73.81%的无应答患者表现出指示稳健免疫(抗-HBs>10)的抗体滴度。
结论：这些发现强调了AS04C佐剂化HB疫苗在解决无反应性方面的关键作用，强调其作为增强各种人群免疫策略的关键工具的潜力。这包括对标准疫苗接种的无应答者，慢性肾病患者，由于免疫抑制或职业危害等因素而需要血清保护的人，以及传统的再接种策略被证明是徒劳的患者。需要进一步的研究来扩展通过我们的协议获得的有希望的结果。
方法：2017年至2021年在西班牙阿尔巴塞特大学医院预防医学服务处进行，这项单中心观察性研究招募了195名患者。其中,在一个或两个完整的标准疫苗接种过程后，126（65％）被归类为无反应者。
结果：在使用完整的四剂量方案的AS04C佐剂疫苗后，73.81%的无应答患者表现出指示稳健免疫(抗-HBs>10)的抗体滴度。
结论：这些发现强调了AS04C佐剂化HB疫苗在解决无反应性方面的关键作用，强调其作为增强各种人群免疫策略的关键工具的潜力。这包括对标准疫苗接种的无应答者，慢性肾病患者，由于免疫抑制或职业危害等因素而需要血清保护的人，以及传统的再接种策略被证明是徒劳的患者。需要进一步的研究来扩展通过我们的协议获得的有希望的结果。
